PRIMARY STUDY
A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
Key Findings: In patients at high risk for psychosis, compared to placebo, a single dose of cannabidiol (CBD) induced greater activation of fear processing centers in the brain and altered the neural circuitry associated with psychosis. This study also suggests that CBD could present a novel therapeutic agent in the treatment and prevention of high-risk psychosis.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 33
Study Result: Positive
Research Location(s): Netherlands, United Kingdom, United States
Year of Pub: 2020
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Receptors Studied: CB1, GPCR 55, TRPV1
Ligands Studied: Cortisol, Dopamine, Glutamate
Dosage: CBD (600 mg)
Route of Administration: Oral (Ingestion)
Citation: Davies C, et al. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry. 2020; 10:311. doi: 10.1038/s41398-020-0862-2
Authors: Davies C, Wilson R, Appiah-Kusi E, Blest-Hopley G, Brammer M, Perez J, Murray RM, Allen P, Bossong MG, McGuire P, Bhattacharyya S
